–Modest treatment effect of canakinumab may limit clinical role in heart disease, but strong anti-cancer signal sparks interest. Despite questions about its clinical importance, the CANTOS trial is being hailed by experts for finally validating the role of inflammation in heart disease. The cardiovascular benefits in the trial were real but modest. Even more exciting, ...
Ischaemic heart disease
CANTOS validates role of inflammation in heart disease
By Larry Husten
29 Aug 2017